Please assess the completion status of the following clinical trial:

Trial Title: Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed ES-SCLC~* No prior treatment for ES-SCLC~* Measurable disease, as defined by RECIST v1.1. Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation.~* ECOG performance status of 0 or 1~* Life expectancy \>= 3 months~* Adequate hematologic and end-organ function~* For participants receiving therapeutic anticoagulation: stable anticoagulant regimen~* Negative human immunodeficiency virus (HIV) test at screening~* Negative hepatitis B surface antigen (HBsAg) test at screening~* Positive hepatitis B surface antibody (HBsAb) test at screening, or negative HBsAb at screening accompanied by either of the following: Negative total hepatitis B core antibody (HBcAb), or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test. The HBV DNA test must be performed for participants who have a negative HBsAg test, a negative HBsAb test, and a positive total HBcAb test.~* Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test must be performed for participants who have a positive HCV antibody test.~* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception~* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm~Exclusion Criteria:~* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases~* History of leptomeningeal disease~* Uncontrolled tumor-related pain~* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures~* Uncontrolled or symptomatic hypercalcemia~* Active or history of autoimmune disease or immune deficiency~* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan~* Active tuberculosis~* Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina~* History of malignancy other than small cell lung cancer (SCLC) within 5 years prior to initiation of study treatment, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab (Type: EXPERIMENTAL): Participants will receive the following treatment regimens: LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab. Induction treatment will be administered on a 21-day cycle for four cycles. Concurrent radiation therapy will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with atezolizumab. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete